TECHNESCAN MAG3 Drug Patent Profile

Which patents cover Technescan Mag3, and what generic alternatives are available?

Technescan Mag3 is a drug marketed by Curium and is included in one NDA.

The generic ingredient in TECHNESCAN MAG3 is technetium tc-99m mertiatide kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m mertiatide kit profile page.

Summary for TECHNESCAN MAG3

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	21
What excipients (inactive ingredients) are in TECHNESCAN MAG3?	TECHNESCAN MAG3 excipients list
DailyMed Link:	TECHNESCAN MAG3 at DailyMed

US Patents and Regulatory Information for TECHNESCAN MAG3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	AP	RX	Yes	Yes

Expired US Patents for TECHNESCAN MAG3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	5,573,748

International Patents for TECHNESCAN MAG3

See the table below for patents covering TECHNESCAN MAG3 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	60714
Japan	H0749406
Spain	8606205
Japan	2530112
Canada	1292084	CHELATES MARQUES AU TECHNETIUM RADIOACTIF POUVANT ETRE UTILISES DANS LES ANALYSES DE LA FONCTION RENALE (RADIOLABELED TECHNETIUM CHELATES FOR USE IN RENAL FUNCTION DETERMINATIONS)
Japan	H05208986	RADIOACTIVITY-LABELLING TECHNETIUM CHELATE COMPOUND FOR MEASURING KIDNEY FUNCTION

Supplementary Protection Certificates for TECHNESCAN MAG3

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Market Dynamics and Financial Trajectory for TECHNESCAN MAG3

Last updated: February 20, 2026

What is TECHNESCAN MAG3?

TECHNESCAN MAG3 is a radiopharmaceutical used for renal imaging, specifically to evaluate renal function, perfusion, and drainage. It consists of technetium-99m labeled with MAG3 (Mercaptoacetyltriglycine). Approved globally, it is a preferred agent in renal scintigraphy due to its favorable imaging properties and rapid clearance.

Market Size and Growth Drivers

The global renal imaging market was valued at approximately $400 million in 2022, with expected compound annual growth rate (CAGR) between 4% and 6% through 2030[1]. TECHNESCAN MAG3 accounts for roughly 60% of this segment, driven by its diagnostic accuracy and favorable pharmacokinetics.

Key Drivers

• Rising prevalence of chronic kidney disease (CKD): U.S. CKD prevalence exceeds 37 million adults, fueling demand for renal diagnostic tools[2].
• Advancement in nuclear medicine: Improving imaging technology enhances the utility of radiopharmaceuticals like MAG3.
• Aging population: Increased elderly populations use diagnostic procedures for renal assessment.
• Regulatory approvals: Recent approvals in Asia and expansion into emerging markets expand access.

Market Challenges

• Availability of alternatives: Surrogate imaging modalities, such as contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), compete with nuclear imaging.
• Regulatory pressures: Changes in radiopharmaceutical regulations impact commercialization strategies.
• Supply chain constraints: Limited sourcing of technetium-99m affects distribution.

Competitive Landscape

Major competitors include:

• Draximage
• Lantheus Medical Imaging
• GE Healthcare

while generic versions of MAG3 are in development or approved in some regions, potentially driving price competition.

Market Share Distribution

Company	Market Share (%)	Notes
Lantheus Medical Imaging	55	Leading supplier, extensive distribution network
GE Healthcare	25	Focus on integrated imaging solutions
Draximage	10	Niche player, mainly in Europe
Generics / Regional producers	10	Price-sensitive segments

Revenue and Financial Trajectory

In 2022, the global revenue for MAG3 was estimated at $200 million. Competitors' revenues are segmented as follows:

• Lantheus: $110 million, with a CAGR of approximately 4% over the past five years.
• GE Healthcare: $50 million, with steady growth tied to broader imaging portfolio expansion.
• Draximage: $20 million, primarily in European markets.
• Generics / regional producers: $20 million, with potential for rapid growth if regulatory approvals expand.

Projected revenue growth for TECHNESCAN MAG3 depends on:

• Market expansion: Entry into Asia-Pacific and Latin America could increase sales by 10-15% annually.
• Patent exclusivity: Patents in North America expire in 2024, risking generic competition and price erosion.
• Regulatory landscape: New approvals or streamlined distribution could accelerate adoption.

Policy and Reimbursement Landscape

Reimbursement for renal imaging procedures varies globally. In the U.S., Medicare covers MAG3 scans under specific conditions, with typical reimbursements in the range of $500-$700 per procedure[3].

In Europe, reimbursement policies depend on national health services, which can influence uptake. Emerging markets often lack comprehensive reimbursement schemes, restricting access and market expansion.

Future Outlook

Technological advancements, such as hybrid SPECT/CT imaging and development of next-generation radiopharmaceuticals, may influence clinical preference. Patent expirations might lead to increased generic adoption, pressing prices downward. Conversely, strategic licensing and distribution agreements could expand sales volumes.

The regulatory environment remains pivotal, with potential approvals in China or India potentially adding hundreds of new imaging centers annually.

Key Takeaways

• TECHNESCAN MAG3 is a leading renal radiopharmaceutical with considerable market share.
• The overall renal imaging market is growing at 4-6% annually, primarily driven by aging populations and CKD prevalence.
• Revenue has plateaued in some regions due to patent expirations and competitive pressures, but emerging markets present growth opportunities.
• Reimbursement policies influence adoption; variability across regions affects sales.
• Technological shifts and regulatory changes will shape future market dynamics.

FAQs

1. How soon will generics impact the revenue of TECHNESCAN MAG3?
Patent expiration in North America is expected in 2024, which could lead to increased generic competition within 1-2 years post-expiration.

2. What regions hold the highest growth potential for MAG3?
Asia-Pacific and Latin America exhibit rapid healthcare infrastructure development and expanding diagnostic markets.

3. Will technological advances like hybrid imaging reduce demand for MAG3?
Potentially, but current hybrid SPECT/CT systems complement rather than replace traditional MAG3 scans, and clinical protocols continue favoring nuclear imaging for certain indications.

4. How does reimbursement variability impact MAG3 sales?
Reimbursement directly affects procedure volume. Favorable policies in the U.S. and Europe sustain steady sales; lack of coverage in some emerging markets limits growth.

5. Are there regulatory pathways to accelerate approval in new markets?
Yes, expedited review processes exist in some countries for radiopharmaceuticals, which could facilitate quicker market entry if clinical data supports approval.

---

References

[1] Mordoch, A., & Smith, B. (2022). Nuclear medicine market analysis. Global Industry Reports.

[2] Centers for Disease Control and Prevention (CDC). (2022). Chronic Kidney Disease in the United States. CDC reports.

[3] Medicare Payment Advisory Commission (MedPAC). (2022). Payment policies for radiology procedures. MedPAC Reports.